Emmes and Casimir Announce Research About a Novel, Home-Based Assessment for Duchenne Muscular Dystrophy

Published on :

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Casimir’s research on the development of the Duchenne Video Assessment (DVA) scorecards was published in PLOS ONE. Emmes acquired Casimir in March 2022, and the group is now part of Emmes’ Rare Disease Center, Orphan Reach™.

Emmes Acquires Casimir, Its Fourth Major Acquisition

Published on :

Emmes (the “Company”), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation and a portfolio company of Behrman Capital, today announced that it has acquired Casimir. A U.S.-based CRO, Casimir has experience in more than 20 rare diseases and has worked with regulators, sponsors and patients to develop outcome measures that capture the nuances of disease progression and treatment benefit. Terms of the transaction were not disclosed.